Life-threatening symptomatic bradycardia can occur when the antiarrhythmia drug amiodarone is taken with either of 2 hepatitis C treatments containing sofosbuvir in combination with another direct-acting antiviral drug, the Food and Drug Administration (FDA) has warned (http://1.usa.gov/1xBtd8o).
The warning concerns Harvoni, which combines sofosbuvir and ledipasvir, and Sovaldi, which is the brand name for sofosbuvir alone. Physicians should not prescribe either drug in combination with another direct-acting antiviral, such as the investigational drug daclatasvir or Olysio, the brand name for simeprevir, and amiodarone.
Rubin R. Warning for Hepatitis C Treatments Given With Amiodarone. JAMA. 2015;313(17):1704. doi:10.1001/jama.2015.4116